Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Salbutamol HFA-152a vs HFA-134a in Asthma
NCT06261957Phase 3Completed
- Sponsor
- GSK
- Start
- May 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of salbutamol in asthma (2 arms), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events During Run-in Period at 1 week and Number of Participants With Adverse Events During Treatment Period at 13 weeks. Started May 2024; status: completed.
02
Drugs
salbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06261957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06261957.